Large gap with delayed quotes
|
Last quote
10/17/2026
-
02:00:00
|
Bid
10/16/2026 -
21:59:59
|
Bid Volume |
Ask
10/16/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
54.68
-1.37
(
-2.44% )
|
54.67
|
200 |
54.70
|
8,800 |
Analysis date: 13.10.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 25.09.2026.
Quality
Very weak
Very weak
One star since 09.10.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 09.10.2026 at a price of 54.80.
Evaluation
Strongly undervalued
Strongly undervalued
Based on its growth potential and our own criteria, we believe the share price is currently undervalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 25.09.2026.
4wk Rel Perf
-19.14%
-19.14%
The four-week dividend-adjusted underperformance versus SP500 is 19.14%.
Risk
Middle
Middle
Moderate, no change over 1 year.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.52%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.93%.
Mkt Cap in $bn
10.72
10.72
With a market capitalization >$8bn, BIOMARIN PHARMA is considered a large-cap stock.
G/PE Ratio
1.27
1.27
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
8.41
8.41
The estimated PE is for the year 2029.
LT Growth
10.66%
10.66%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
12
12
Over the last seven weeks, an average of 12 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
19
19
For 1% of index variation, the stock varies on average by 0.19%.
Correlation
0.07
0.07
Stock movements are totally independent of index variations.
Value at Risk
6.74
6.74
The value at risk is estimated at USD 6.74. The risk is therefore 12.39%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.05.2003
21.05.2003